Albert Anderson, MD
Family Medicine · Indio, CANPI 1013002435
Payments from drug & device makers
Across 87 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$629
- Johnson & Johnson$229
- GSK$200
- Neurocrine Biosciences, Inc.$145
- Boston Scientific$133
- Amgen$92
- plus $577 from 15 others
What the payments were for
- Food & beverage$2,005100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $629 |
| Johnson & Johnson | 14 | $229 |
| GSK | 13 | $200 |
| Neurocrine Biosciences, Inc. | 2 | $145 |
| Boston Scientific | 1 | $133 |
| Amgen | 4 | $92 |
| Boehringer Ingelheim | 3 | $84 |
| Shield Therapeutics Inc | 2 | $66 |
| Lilly USA, LLC | 3 | $58 |
| Bayer | 3 | $55 |
| Pfizer | 3 | $50 |
| Hologic Sales And Service, LLC | 1 | $45 |
| Novo Nordisk | 2 | $40 |
| AbbVie | 2 | $38 |
| Merck | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Viiv Healthcare Company | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Cequr Corporation | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,005 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynjardyEmpagliflozin/Metformin Hcl | 218 | $244,478 |
| JardianceEmpagliflozin | 152 | $206,153 |
| EliquisApixaban | 201 | $196,238 |
| OzempicSemaglutide | 153 | $141,493 |
| FarxigaDapagliflozin Propanediol | 99 | $109,745 |
| JanuviaSitagliptin Phosphate | 77 | $105,876 |
| TrulicityDulaglutide | 78 | $80,082 |
| XareltoRivaroxaban | 52 | $66,304 |
| TradjentaLinagliptin | 39 | $49,462 |
| ProliaDenosumab | 28 | $49,158 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $44,894 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $43,847 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 100 | $42,527 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 42 | $38,426 |
| MounjaroTirzepatide | 25 | $27,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy, Jardiance, Tradjenta, Stiolto Respimat, Combivent Respimat | $84 | $531,109470 claims |
| PfizerEliquis | $50 | $196,238201 claims |
| Novo NordiskOzempic, Rybelsus | $40 | $166,798165 claims |
| MerckJanuvia, Janumet | $35 | $129,86398 claims |
| AstraZenecaFarxiga | $629 | $109,74599 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $58 | $108,020103 claims |
| Johnson & JohnsonXarelto, Invokana | $229 | $79,69064 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $200 | $68,246101 claims |
| AmgenProlia | $92 | $49,15828 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $13 | $44,43277 claims |
| AbbVieCreon | $38 | $14,40316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Indio
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.